COVID‐19 Affects Short‐Term, But Not 90‐Day, Outcome in Patients With Stroke Treated With Mechanical Thrombectomy

IF 2.1 Q3 CLINICAL NEUROLOGY
N. M. Beckonert, F. Bode, F. Dorn, S. Stösser, Julius N Meissner, J. Nordsiek, C. Kindler, Taraneh Ebrahimi, Christoph Riegler, C. Nolte, G. Petzold, Johannes M. Weller
{"title":"COVID‐19 Affects Short‐Term, But Not 90‐Day, Outcome in Patients With Stroke Treated With Mechanical Thrombectomy","authors":"N. M. Beckonert, F. Bode, F. Dorn, S. Stösser, Julius N Meissner, J. Nordsiek, C. Kindler, Taraneh Ebrahimi, Christoph Riegler, C. Nolte, G. Petzold, Johannes M. Weller","doi":"10.1161/svin.123.000915","DOIUrl":null,"url":null,"abstract":"\n \n COVID‐19 is associated with an increased stroke risk. Moreover, outcome at discharge was worse in patients with large‐vessel occlusion stroke with concomitant COVID‐19 receiving endovascular treatment (ET). We aimed to investigate the impact of concomitant COVID‐19 on later functional outcome in patients with large‐vessel occlusion stroke treated with ET.\n \n \n \n We analyzed patients from the GSR‐ET (German Stroke Registry–Endovascular Treatment), an observational multicenter registry of patients with large‐vessel occlusion stroke receiving ET. Baseline characteristics, procedural parameters, discharge parameters, and functional outcome at 90 days were compared between patients with concomitant COVID‐19 and propensity score–matched controls (ratio, 1:4; matched for age, sex, prestroke modified Rankin Scale score, and stroke severity), and multivariable ordinal regression analysis was performed.\n \n \n \n \n Among 4010 patients receiving ET between February 2020 and December 2021, 72 (1.8%) had concomitant COVID‐19. Compared with 224 matched patients without COVID‐19, they (n=56) were more severely affected, with a higher median National Institutes of Health Stroke Scale (NIHSS) score after 24 hours (NIHSS score, 14.5 [interquartile range {IQR}, 9–22] versus 12 [IQR, 6–18.75];\n P\n =0.015), and NIHSS score and modified Rankin Scale score at discharge (NIHSS score, 12 [IQR, 6.75‐16.75] versus 6 [IQR, 2–13];\n P\n =0.001; and modified Rankin Scale score, 5 [IQR, 4–5] versus 4 [IQR, 2–5];\n P\n =0.023), but functional outcome at 90‐day follow‐up was similar (modified Rankin Scale score, 4 [IQR, 4–6] versus 4 [IQR, 2–6];\n P\n =0.34). After adjustment for prespecified confounders, COVID‐19 was associated with worse functional outcome at discharge (common odds ratio [OR], 0.40 [95% CI, 0.19–0.80];\n P\n =0.011), but not at 90‐day follow‐up (common OR, 0.72 [95% CI, 0.32–1.60];\n P\n =0.43).\n \n \n \n \n COVID‐19 affected short‐term, but not 90‐day, functional outcome in patients with large‐vessel occlusion stroke treated with ET. Hence, ET should not be withheld in patients with concomitant COVID‐19.\n","PeriodicalId":74875,"journal":{"name":"Stroke (Hoboken, N.J.)","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stroke (Hoboken, N.J.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/svin.123.000915","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

COVID‐19 is associated with an increased stroke risk. Moreover, outcome at discharge was worse in patients with large‐vessel occlusion stroke with concomitant COVID‐19 receiving endovascular treatment (ET). We aimed to investigate the impact of concomitant COVID‐19 on later functional outcome in patients with large‐vessel occlusion stroke treated with ET. We analyzed patients from the GSR‐ET (German Stroke Registry–Endovascular Treatment), an observational multicenter registry of patients with large‐vessel occlusion stroke receiving ET. Baseline characteristics, procedural parameters, discharge parameters, and functional outcome at 90 days were compared between patients with concomitant COVID‐19 and propensity score–matched controls (ratio, 1:4; matched for age, sex, prestroke modified Rankin Scale score, and stroke severity), and multivariable ordinal regression analysis was performed. Among 4010 patients receiving ET between February 2020 and December 2021, 72 (1.8%) had concomitant COVID‐19. Compared with 224 matched patients without COVID‐19, they (n=56) were more severely affected, with a higher median National Institutes of Health Stroke Scale (NIHSS) score after 24 hours (NIHSS score, 14.5 [interquartile range {IQR}, 9–22] versus 12 [IQR, 6–18.75]; P =0.015), and NIHSS score and modified Rankin Scale score at discharge (NIHSS score, 12 [IQR, 6.75‐16.75] versus 6 [IQR, 2–13]; P =0.001; and modified Rankin Scale score, 5 [IQR, 4–5] versus 4 [IQR, 2–5]; P =0.023), but functional outcome at 90‐day follow‐up was similar (modified Rankin Scale score, 4 [IQR, 4–6] versus 4 [IQR, 2–6]; P =0.34). After adjustment for prespecified confounders, COVID‐19 was associated with worse functional outcome at discharge (common odds ratio [OR], 0.40 [95% CI, 0.19–0.80]; P =0.011), but not at 90‐day follow‐up (common OR, 0.72 [95% CI, 0.32–1.60]; P =0.43). COVID‐19 affected short‐term, but not 90‐day, functional outcome in patients with large‐vessel occlusion stroke treated with ET. Hence, ET should not be withheld in patients with concomitant COVID‐19.
COVID - 19对机械取栓治疗的脑卒中患者短期而非90天的预后有影响
新冠肺炎与中风风险增加有关。此外,接受血管内治疗(ET)的大血管闭塞性中风伴新冠肺炎患者出院时的预后更差。我们旨在研究伴随新冠肺炎-19对接受ET治疗的大血管闭塞性卒中患者后期功能结果的影响,比较伴有COVID-19的患者和倾向评分匹配的对照组(比例为1:4;年龄、性别、卒中前改良Rankin量表评分和卒中严重程度匹配)在90天时的出院参数和功能结果,并进行多变量有序回归分析。在2020年2月至2021年12月期间接受ET治疗的4010名患者中,72人(1.8%)伴有新冠肺炎。与224名未感染新冠肺炎的匹配患者相比,他们(n=56)受到的影响更严重,24小时后美国国立卫生研究院卒中量表(NIHSS)评分中值更高(NIHSS评分,14.5[四分位间距{IQR},9-22],而12[IQR,6-18.75];P=0.015),以及出院时的NIHSS评分和改良兰金量表评分(NIHSS评分,12[IQR,6.75-16.75]对6[IQR,2-13];P=0.001;改良兰金表评分,5[IQR,4-5]对4[IQR,2-5];P=0.023),但90天随访时的功能结果相似(改良兰金度表评分,4[IRR,4-6]对4[IQR,2-6];P=0.034)。在调整了预先指定的混杂因素后,新冠肺炎与出院时更差的功能结果相关(常见比值比[OR],0.40[95%CI,0.19-0.80];P=0.011),但与90天随访时无关(常见比值率,0.72[95%CI;0.32-1.60];P=0.043)。新冠肺炎影响ET治疗的大血管闭塞性卒中患者的短期但不影响90天的功能结果。因此,不应在伴有新冠肺炎-19的患者中保留ET。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信